Role of ivabradine in postoperative tachyarrhythmias after congenital cardiac surgery
This retrospective study of 55 patients undergoing congenital cardiac surgery demonstrates that ivabradine monotherapy is an effective and safe first-line treatment for postoperative automaticity-driven tachyarrhythmias, particularly junctional ectopic tachycardia, though a subset of patients may require adjunctive therapy to achieve rhythm control.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a child undergoes surgery to repair a heart defect, the heart muscle is often left temporarily irritable. In the days following the operation, this irritation can cause the heart to beat too fast, a condition known as a tachyarrhythmia. While a fast heartbeat might seem like a simple reaction to stress, in the delicate environment of a recovering pediatric heart, it can be dangerous. The most common culprit is a specific type of rapid rhythm called junctional ectopic tachycardia, where the heart's natural pacemaker signals get confused, causing the lower chambers to fire too quickly. For decades, doctors have treated these dangerous rhythms with powerful medications like amiodarone. However, these drugs often come with a heavy price: they can drop blood pressure dangerously low or cause other serious side effects, which is particularly risky for children who may not have access to advanced life-support machines. This creates a difficult dilemma for surgeons and cardiologists: how to calm a racing heart without weakening the patient's ability to recover.
A team of researchers at the National Institute of Cardiovascular Disease in Karachi, Pakistan, set out to explore a different path. They investigated the use of a drug called ivabradine, which works by gently slowing down the electrical signals that tell the heart to beat, rather than forcefully suppressing the heart's overall function. Their goal was to see if this gentler approach could safely manage the rapid heartbeats that frequently occur after congenital heart surgery. The researchers looked back at the records of 55 children who had developed these postoperative rhythm problems between January 2024 and June 2025. All of these children had received ivabradine, either as the sole treatment or alongside other medications, after their hearts began to race following surgery.
The study focused on children who were generally stable enough to receive oral medication. Among the 55 patients, the most common problem was indeed junctional ectopic tachycardia, affecting 42 children. The remaining patients had other types of fast rhythms, such as ectopic atrial tachycardia or inappropriate sinus tachycardia. The researchers found that for the majority of these children, ivabradine alone was enough to bring the heart rate back to a normal rhythm. Specifically, 38 of the 55 patients, or about 69 percent, were successfully treated with just the single drug. These children saw their heart rates return to normal within a day, and they were able to leave the intensive care unit and the hospital much sooner than those who needed more complex treatment.
However, the drug did not work for everyone. About 31 percent of the children, or 17 patients, required additional medication to control their heart rates. These children tended to be the ones with the fastest heart rates when the arrhythmia started, and they took significantly longer to recover, with their heart rates stabilizing after three days instead of one. Consequently, they also spent more time in the hospital. The researchers noted that the children who needed extra help were often in a more critical condition, with lower blood flow that might have made it harder for the oral medication to be absorbed properly. In these cases, doctors added other drugs, most commonly amiodarone, to the treatment plan. Importantly, the study observed no significant drop in blood pressure or other harmful side effects from the ivabradine itself, suggesting it is a safe option for children who are hemodynamically stable.
The findings suggest that ivabradine is a highly effective first-line tool for managing the most common fast heart rhythms after congenital heart surgery, offering a safer alternative to older, more toxic drugs for many patients. It appears to work best when the child is stable enough to absorb the medicine and does not have severe complications. For the most critically ill children, or those whose heart rates remain dangerously high despite the initial treatment, the drug may need to be paired with other therapies to ensure safety. While this study was retrospective and looked at past cases rather than running a new controlled experiment, the results provide strong evidence that this gentler approach can significantly improve recovery times for a large portion of pediatric cardiac patients. The work highlights a shift in how doctors might manage these delicate postoperative moments, prioritizing a medication that calms the heart's electrical signals without compromising the patient's overall strength.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.